Preview

Rheumatology Science and Practice

Advanced search

Evaluation of the clinical efficiency of tocilizumab therapy, by using DAS 28, SDAI, CDAI indices and new 2011 EULAR/ACR remission criteria in patients with rheumatoid arthritis

https://doi.org/10.14412/1995-4484-2012-1268

Abstract

Objective: to evaluate the clinical efficiency of tocilizumab (TCZ) from the DAS 28, SDAI, and CDAI indices and to estimate remission rates from the European League Against Rheumatism (EULAR) criteria, and the new remission criteria proposed by the EULAR and the American College of Rheumatology (ACR) in 2011. Subjects and methods. Forty-two patients with rheumatoid arthritis (RA) who had received 6 infusions of TCZ in an intravenous dose of 8 mg/kg at a 4-week interval during stable therapy with disease-modifying antirheumatic drugs (DMARDs) and glucocorticoids were examined. The EULAR criteria based on changes in the DAS 28 index and the SDAI and CDAI activity indices were used to evaluate the efficiency of TCZ therapy. Disease remission was assessed by the EULAR criteria and the new 2011 EULAR/ACR remission criteria. Results. The baseline values (median and interquartile range: 25-75th percentiles) were 6.44 (5.87-7.04) for DAS 28; 45 (36.2-57) for SDAI; and 41.5 (32-53) for CDAI. At week 2 of TCZ therapy, there was a reduction in the levels of DAS 28 to 4.86 (4.28-5.29) and at week 4, there were decreases in SDAI to 22.6 (19.4-29.3) and CDAI to 21.9 (19.3-30), which remained until week 24 (p < 0.01). By week 24 of TCZ therapy, according to the EULAR criteria, 35 and 7 patients were observed to have good and moderate effects, respectively. By week 24, 30 (71%), 13 (31%), and 14 (33%) patients achieved remission according to DAS 28, SDAI, and CDAI, respectively; low DAS 28 (2.6-3.2), SDAI (3.3-11), and CDAI (2.8-10) disease activity was observed in 5 (12%), 21 (50%), and 20 (47.6%) patients, respectively; high SDAI and CDAI activities remained in 2 (4.8%) patients. Remission was observed in 10 (24%) patients according to the 2011 criteria. Conclusion. The obtained results of the 24-week study suggest that TCZ therapy is highly effective according to the changes in DAS 28, SDAI, CDAI activity indices and to the new 2011 EULAR/ACR remission criteria in severe RA resistant to the standard treatment with DMARDs.

References

1. <div><p>Насонов Е.Л., Каратеев Д.Е., Балабанова Р.М. Ревматоидный артрит. В кн.: Ревматология. Национальное руководство. Под ред. Е.Л. Насонова, В.А.Насоновой. М.: ГЭОТАР-Медиа, 2008;290—331.</p><p>Насонов Е.Л., Панасюк Е.Ю., Булдаков С.Г. и др. Эффективность и безопасность тоцилизумаба при ревматоидном артрите (промежуточные результаты российского многоцентрового исследования). Науч-практич ревматол 2009;2:21-9.</p><p>Smolen J.S., Beaulieu A., Rubbert-Roth A. et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987-97.</p><p>Genovese M.C., McKay J.D., Nasonov E.L. et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthr Rheum 2008;58:2968-80.</p><p>Emery P., Keystone E., Tony H.P. et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516-23.</p><p>Nishimoto N., Hashimoto J., Miyasaka N. et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007;66:1162-7.</p><p>Nishimoto N., Miyasaka N., Yamamoto K. et al. Study of active controlled tocilizumab mono-therapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol 2009;19:12-9.</p><p>Jones G., Sebba A., Gu J. et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010;69:88-96.</p><p>Burmester G., Feist E., Kellner H. et al. Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). Ann Rheum Dis 2011;70:755-9.</p><p>Fleischmann R., Burgos-Vargas R., Skopouli F.N. et al. Tocilizumab inhibits radiographic progression, improves physical function, and gains efficacy over time: LITHE 2 year. Ann Rheum Dis 2010;69(Suppl. 3):384.</p><p>Smolen J.S., Aletaha D., Bijsma J.W.J. et al. For the T2T Exspert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.</p><p>Fransen J., Stucki G., van Reil P.L.C.M. Rheumatoid arthritis measures. Arthr Rheum 2003;49:214-24.</p><p>Prevoo M., van't Hof M., Kuper H. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthr Rheum 1995;38:44-8.</p><p>Smolen J., Breedveld F., Schiff M. et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 2003;42:244-57.</p><p>Aletaha D., Nell V., Stamm T. et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthr Res Ther 2005;7:796-806.</p><p>Rintelen B., Sautner J., Haindl P. et al. Comparison of three rheumatoid arthritis disease activity scores in clinical routine. Scand J Rheumatol 2009;38:336-41.</p><p>Shaver T.S., Anderson J.D., Weidensaul D.N. et al. The problem of rheumatoid arthritis disease activity and remission in clinical practice. J Rheumatol 2008;35:1015-22.</p><p>Felson D., Smolen J.,Wells G. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthr Rheum 2011;63:573-86.</p><p>Kawashiri S., Kawakami A., Iwamoto N. et al. In rheumatoid arthritis patients treated with tocilizumab, the rate of clinical disease activity index (CDAI) remission at 24 weeks is superior in those with higher titers of IgM-rheumatoid factor at baseline. Mod Rheumatol 2011;21;370-4.</p><p>Smolen J., Alasti F., Aletaha D. Application of the clinical disease activity index (SDAI) which does not comprise an acute phase reactant (APR) reveals the efficacy of tocilizumab irrespective of the inclusion of an APR for assessment of response. Ann Rheum Dis 2009;68(Suppl. 3):355.</p><p>Aletaha D., Alasti F., Smolen J. Defining remission in patients receiving tocilizumab is influenced by the choice of the composite index rather than by specific effects on the acute phase response. Ann Rheum Dis 2009;68(Suppl. 3):123.</p><p>Nakazaki S., Murayama T., Kato S. The validity of 28-joint disease activity scoring using ESR in rheumatoid arthritis with tocilizumab. Ann Rheum Dis 2011;70(Suppl. 3):618.</p><p>Funahashi K., Koyano S., Miura T. et al. Efficacy of tocilizumab and evaluation of clinical remission as determined by CDAI and MMP-3 level. Mod Rheumatol 2009;19:507-12.</p><p>Koyama Y., Tada T., Ohta T., Fujii K. Reevaluation of quantitative assessment methods of rheumatoid arthritis should be considered for the treatment with anti-IL-6 receptor antibody. Ann Rheum Dis 2009;68(Suppl. 3):582.</p><p>Leffers H., Ostergaard M., Glintborg B. Rheumatoid arthritis patients treated in routine care - efficacy of abatacept and tocilizumab based on data from the nationwide Danish DANBIO registry. Ann Rheum Dis 2011;70(Suppl. 3):463.</p><p>Yoshida K., Kishimoto M., Tokuda Y. Tocilizumab vs TNF inhibitors: difference in the quality of remission. Ann Rheum Dis 2011;70(Suppl. 3):470.</p><p>Sibilia J., Graninger W., Ostor A. et al. Comparison of tocilizumab as monotherapy or with add-on DMARDS in patients with rheumatoid arthritis and an inadequate response to previous treatments: ACT-SURE results. Ann Rheum Dis 2011;70(Suppl. 3):466.</p><p>Iking-Konert C., Aringer M., Wollenhaupt J. et al. Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study TAMARA as an example and their comparison with traditional remission criteria. Ann Rheum Dis 2011;70:1986-90.</p><p>Kojima T., Kaneko A., Hirano Y. et al. Early aggressive intervention with tocilizumab for rheumatoid arthritis increases remission rate defined using a Boolean approach in clinical practice. Mod Rheumatol (Doi 10.1007/s10165-011-0528-2).</p><p>Smolen J., Aletaha D. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis. Arthr Rheum 2011;63:43-52.</p></div><br />


Review

For citations:


Avdeyeva A.S., Panasyuk E.Yu., Aleksandrova E.N., Nasonov E.L. Evaluation of the clinical efficiency of tocilizumab therapy, by using DAS 28, SDAI, CDAI indices and new 2011 EULAR/ACR remission criteria in patients with rheumatoid arthritis. Rheumatology Science and Practice. 2012;50(2):20-24. (In Russ.) https://doi.org/10.14412/1995-4484-2012-1268

Views: 1552


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)